Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) EBT (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed EBT for 7 consecutive years, with -$13.9 million as the latest value for Q2 2025.

  • Quarterly EBT fell 200.13% to -$13.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$24.8 million through Jun 2025, down 14.76% year-over-year, with the annual reading at -$38.5 million for FY2025, 78.26% down from the prior year.
  • EBT hit -$13.9 million in Q2 2025 for Benitec Biopharma, down from -$4.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$1.4 million in Q4 2024 to a low of -$13.9 million in Q2 2025.
  • Historically, EBT has averaged -$5.1 million across 5 years, with a median of -$4.6 million in 2022.
  • Biggest five-year swings in EBT: skyrocketed 80.21% in 2024 and later tumbled 200.13% in 2025.
  • Year by year, EBT stood at -$4.8 million in 2021, then dropped by 15.95% to -$5.6 million in 2022, then dropped by 23.38% to -$6.9 million in 2023, then surged by 80.21% to -$1.4 million in 2024, then tumbled by 912.39% to -$13.9 million in 2025.
  • Business Quant data shows EBT for BNTC at -$13.9 million in Q2 2025, -$4.3 million in Q1 2025, and -$1.4 million in Q4 2024.